Adds details throughout

June 9 (Reuters) - Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.

The Cambridge, Massachusetts-based company is now marketing 33.3 million shares priced between $17 and $19. It had earlier planned to sell 25 million shares in the offering.

Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities and LifeSci Capital are the underwriters for the offering.

Parabilis is expected to begin trading on the Nasdaq under the symbol “PBLS” on Wednesday.